Search hospitals > New York > Syracuse
SUNY Upstate Medical Center-Community Campus
Claim this profileSyracuse, New York 13215
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Skin Cancer
34 reported clinical trials
12 medical researchers
Summary
SUNY Upstate Medical Center-Community Campus is a medical facility located in Syracuse, New York. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, Skin Cancer and other specialties. SUNY Upstate Medical Center-Community Campus is involved with conducting 34 clinical trials across 69 conditions. There are 12 research doctors associated with this hospital, such as Mary Cunningham, M.D., Stephen L. Graziano, Michael D. Mix, and Alina Basnet.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
2Breast Cancer
Global LeaderHER2 negative
HER2 positive
ER positive
Top PIs
Mary Cunningham, M.D.State University of New York Upstate Medical University2 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
49 drugs studied
Stephen L. GrazianoState University of New York Upstate Medical University5 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
45 drugs studied
Michael D. MixState University of New York Upstate Medical University7 years of reported clinical research
Studies Lung Cancer
Studies Small Cell Lung Cancer
11 reported clinical trials
31 drugs studied
Alina BasnetState University of New York Upstate Medical University2 years of reported clinical research
Studies Bladder Cancer
Studies Cancer
9 reported clinical trials
17 drugs studied
Clinical Trials running at SUNY Upstate Medical Center-Community Campus
Lung Cancer
Skin Cancer
Breast Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Breast cancer
Oropharyngeal Carcinoma
Cancer
Pancreatic Neuroendocrine Tumors
Brain Tumor
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at SUNY Upstate Medical Center-Community Campus?
SUNY Upstate Medical Center-Community Campus is a medical facility located in Syracuse, New York. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, Skin Cancer and other specialties. SUNY Upstate Medical Center-Community Campus is involved with conducting 34 clinical trials across 69 conditions. There are 12 research doctors associated with this hospital, such as Mary Cunningham, M.D., Stephen L. Graziano, Michael D. Mix, and Alina Basnet.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.